General
Preferred name
Lorediplon
Synonyms
Gf-015535-00 ()
P&D ID
PD012259
CAS
917393-39-6
Tags
available
drug candidate
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lorediplon is a novel non-benzodiazepine drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit, associated with promoting sleep.;Target: GABA;Lorediplon is a drug for the treatment of insomnia, has been successfully completed with a best-in-class efficacy profile in terms of maintaining sleep and sleep quality, Lorediplon targets GABAA. [1] Lorediplon demonstrates a minimum of 10-fold and 6-fold increase in potency (respectively) in the spontaneous motor activation studies. At concentrations of 1.2mg/kg, Lorediplon demonstrates a 57%increased effect on Slow Wave Sleep (SWS), when compared with a placebo.[2]
PRICE 32
DESCRIPTION Lorediplon is a novel hypnotic drug acting as a GABAA receptor modulator, differentially active at the ??1-subunit, associated with promoting sleep.
DESCRIPTION Lorediplon is a hypnotic drug acting as a GABAA receptor modulator, differentially active at the alpha1-subunit. It is a novel nonbenzodiazepine of the pyrazolopyrimidine family. It is a drug for the treatment of insomnia. It demonstrated a dose-dependent improvement in sleep. It has been successfully completed with a best-in-class efficacy profile in terms of maintaining sleep and sleep quality. It demonstrates a minimum of 10-fold and 6-fold increase in potency in the spontaneous motor activation studies. It was developed by Ferrer and has been in Cilinic Phase 2. (BOC Sciences Bioactive Compounds)
DESCRIPTION Lorediplon is a novel hypnotic drug acting as a GABAA receptor modulator, differentially active at the α1-subunit, associated with promoting sleep. (TargetMol Bioactive Compound Library)
Compound Sets
8
AdooQ Bioactive Compound Library
A13449
BOC Sciences Bioactive Compounds
lorediplon-cas-917393-39-6-item-474909
Cayman Chemical Bioactives
23868
ChEMBL Drugs
CHEMBL4303403
Drug Repurposing Hub
MedChem Express Bioactive Compound Library
HY-19371
ReFrame library
TargetMol Bioactive Compound Library
TQ0023
External IDs
16
Properties
(calculated by RDKit )
Molecular Weight
394.09
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
0
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
4
cLogP
3.81
TPSA
67.57
Fraction CSP3
0.1
Chiral centers
0.0
Largest ring
6.0
QED
0.49
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
GABA Receptor
GABAA
GABRA1
MOA
GABA Receptor modulator
Pathway
Membrane Transporter/Ion Channel
Neuroscience
Neuronal Signaling
Solubility
10 mM in DMSO
Source data